Who
Garheng Kong
Director
Company insider
Files Form 4 as: Director, Xeris Biopharma Holdings; Director, Labcorp Holdings; Director and 10% owner, Venus Concept; Director and 10% owner, Alimera Sciences; Director, Strongbridge Biopharma; 10% owner and Other, Castle Biosciences; Director, Avedro; Director, Ocugen.
In numbers
- Trades disclosed
- 142
- Buys
- 4
- Sells
- 3
- Bought
- $5.0M
- Sold
- $9.4M
- Companies
- 9
- Companies where not an officer
- 9
- First trade
- 20 Mar 2012
- Last trade
- 4 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —24,193 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | $203K32,996 at $6.15 | filing |
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | $203K32,996 at $6.15 | filing |
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —24,193 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | LH Labcorp HoldingsDiagnostics & Labs | SEC FORM 4 Code M | —897 | filing |
| 11 Feb 2026filed 13 Feb 2026 | LH Labcorp Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —897 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | LH Labcorp Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —897 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | LH Labcorp HoldingsDiagnostics & Labs | SEC FORM 4 Code M | —897 | filing |
| 10 Feb 2026filed 12 Feb 2026 | LH Labcorp Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —773 at $0.00 | filing |
| 10 Feb 2026filed 12 Feb 2026 | LH Labcorp Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —773 at $0.00 | filing |
| 4 Jun 2025filed 4 Jun 2025 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 11 Feb 2025filed 13 Feb 2025 | LH Labcorp Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —897 at $0.00 | filing |
| 6 Feb 2025filed 10 Feb 2025 | LH Labcorp Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —944 at $0.00 | filing |
| 6 Feb 2025filed 10 Feb 2025 | LH Labcorp HoldingsDiagnostics & Labs | SEC FORM 4 Code M | —944 | filing |
| 5 Jun 2024filed 5 Jun 2024 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 15 Mar 2024filed 1 Apr 2024 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code J | —6,474 | filing |
| 7 Feb 2024filed 8 Feb 2024 | LH Labcorp Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —947 at $0.00 | filing |
| 7 Feb 2024filed 8 Feb 2024 | LH Labcorp HoldingsDiagnostics & Labs | SEC FORM 4 Code M | —947 | filing |
| 6 Feb 2024filed 8 Feb 2024 | LH Labcorp Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —944 at $0.00 | filing |
| 7 Jun 2023filed 7 Jun 2023 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —42,500 at $0.00 | filing |
News
Head to Head Analysis: Castle Biosciences (NASDAQ:CSTL) vs. Alignment Healthcare (NASDAQ:ALHC)CSTL · themarketsdaily.com · 15 Oct 2026Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 3,288 Shares of StockCSTL · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Garheng Kong; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.